Recro Pharma expands CDMO business in Georgia

7th November 2018 Uncategorised 0

Pennsylvania-based Recro Pharma is awaiting a March 24, 2019 PDUFA date for a its IV meloxicam, a non-opioid alternative for moderate to severe pain. Until then it is leaning heavily on its CDMO business and that arm of the operation has just completed an expansion that should help the drug developer boost its revenues.

More: Recro Pharma expands CDMO business in Georgia
Source: fierce